NEWS RELEASE - For Immediate Release

Celsense, Inc. Completes Second Series A Financing

July 16, 2007 - Pittsburgh, Pennsylvania

Celsense, Inc, a provider of reagents and methods for imaging transplanted cells in vivo, announced the successful completion of a second Series A financing. The company placed $720,400 in new Series A securities with a syndicate of private investors.
"We very much appreciate the support of the investment community,” said Charlie O’Hanlon, President and CEO of Celsense.

About Celsense, Inc. – Celsense is a Pittsburgh-based biotechnology company offering products and services that enable the real-time in vivo imaging of transplanted cells for therapeutic and diagnostic purposes. The mission of the company is to be the imaging standard for transplanted cells in human health.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.